Page 2 of 8, showing 50 records out of 368 total, starting on record 51, ending on 100
| Publication |
Category |
Year |
|
35. Labrie, F., Candas, B., Gomez, L.J., Cusan, L. (2002) Can combined androgen blockade provide long term control or possible cure of localized prostate cancer? Urology, 60: 115-119. |
Prostate Cancer |
2002 |
|
36. Crawford, E.D., Miller, G., Labrie, F., Hirano, D., Batuello, J., Globe, M. (2001) Prostate cancer pathology, screening and epidemiology. Reviews in Urology, 3: S2-S10. |
Prostate Cancer |
2001 |
|
37. Gomella, L.G., Labrie, F., Gamito, E.J., Brawer, M.K. (2001) Prostate cancer: risk assessment and diagnostic approaches. Reviews in Urology, 3: S31-S38. |
Prostate Cancer |
2001 |
|
38. Labrie, F. (2001) Le cancer de la prostate: blocage combiné des androgènes comme traitement à tous les stades de la maladie. Oncologie, 3: 3-12. |
Prostate Cancer |
2001 |
|
39. Labrie, F., Candas, B., Cusan, L., Gomez, J.L. (2001) The Laval University screening trial results (Chapter 17), in: Thompson, I.M., Resnick, M.I. et Klein, E.A., eds: Current Clinical Urology, Prostate Cancer Screening, Totowa, NJ, Humana Press Inc., pp 255-279. |
Prostate Cancer |
2001 |
|
40. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. |
Prostate Cancer |
2001 |
|
41. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. |
Prostate Cancer |
2001 |
|
42. Roach III, M.J., Thrasher, J.B., Blasko, J., Raben, D., Stone, N., Katz, A., Labrie, F. (2001) Prostatectomy, brachytherapy, intensity modulated radiotherapy, hormonal-radiotherapy, salvae cryosurgery and the role of combined hormonal blokade in the treatment of prostate cancer. Reviews in Urology, 3: S49-S58. |
Prostate Cancer |
2001 |
|
43. Tavtigian, S.V., Simard, J., Teng, D.H.F., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., Desrochers, M., Dumont, M., Farnham, J.M., Frank, D., Frye, C., Ghaffari, S., Gupte, J.S., Hu, R., Iliev, D., Janecki, T., Kort, E.N., Laity, K.E., Leavitt, A., Leblanc, G., McArthur-Morrison, J., Pederson, A., Penn, B., Peterson, K.T., Reid, J.E., Richards, S., Schroeder, M., Smith, R., Snyder, S.C., Swedlund, B., Swensen, J., Thomas, A., Tranchant, M., Woodland, A.-M., Labrie, F., Skolnick, M.H., Neuhausen, S., Rommens, J., Cannon-Albright, L.A. (2001) A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 27: 172-180. |
Prostate Cancer |
2001 |
|
44. Candas, B., Cusan, L., Gomez, J.-L., Diamond, P., Suburu, R.E., Lévesque, J., Brousseau, G., Bélanger, A., Labrie, F. (2000) Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate, 45: 19-35. |
Prostate Cancer |
2000 |
|
45. El-Alfy, M., Pelletier, G. Hermo, L.S., Labrie, F. (2000) Unique features of the basal cells of human prostate epithelium. Microsc. Res. Tech., 51: 436-446. |
Prostate Cancer |
2000 |
|
48. Labrie, F. (2000) Prostate cancer and combined androgen blockade at all stages of disease, in: Khayat, D. et Hortobagyi, G.N., eds: Progress in Anti-Cancer Chemotherapy, France, Springer, pp 171-187. |
Prostate Cancer |
2000 |
|
46. Labrie, F. (2000) Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate, 43: 214-222. |
Prostate Cancer |
2000 |
|
47. Labrie, F. (2000) Screening and hormonal therapy of localized prostate cancer show major benefits on survival. Cancer J. Sci. Am., 6: S182-S187. |
Prostate Cancer |
2000 |
|
49. Labrie, F., Candas, B. (2000) Androgen blockade in prostate cancer [Letter-to-the-Editor]. Lancet, 356: 341-342. |
Prostate Cancer |
2000 |
|
50. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C. (2000) Role of 17beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab., 11: 421-427. |
Prostate Cancer |
2000 |
|
51. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. |
Prostate Cancer |
2000 |
|
52. Pelletier, G., Labrie, C., Labrie, F. (2000) Localization of oestrogen receptor alpha oestrogen receptor beta and androgen receptors in the rat reproductive organs. J. Endocrinol., 165: 359-370. |
Prostate Cancer |
2000 |
|
53. Prostate Cancer Triallist’ Collaborative Group; (2000) Maximum androgen blockade in advanced prostate cancer: an overvierw of the randomised trials. Lancet, 355: 1491-1498. |
Prostate Cancer |
2000 |
|
54. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Badzioch, M., Kote-Jarai, Z., Teare, D., Fortd, D., Dearnaley, D., Ardern-Jones, A., Murkin, A., Dowe, A., Shearer, R., Kelly, J., Labrie, F., Easton, D., Narod, S.A., Tonin, P.N., Foulkes, W.D. (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis., 3: 241-247. |
Prostate Cancer |
2000 |
|
55. Xu, J., The International Consortium for Prostate Cancer Genetics. (2000) Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet., 66: 945-57. |
Prostate Cancer |
2000 |
|
56. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. |
Prostate Cancer |
1999 |
|
806. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. |
Prostate Cancer |
1999 |
|
58. Kelloff, G.J., Lieberman, R., Brawer, M.K., Crawford, E.D., Labrie, F., Miller, G.J. (1999) Strategies for chemoprevention of prostate cancer. Prostate Cancer and Prostatic Diseases, 2: 27-33. |
Prostate Cancer |
1999 |
|
59. Labrie, F. (1999) Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer, in: De Vita, V.T., Hellman, S. et Rosenberg, S.A., eds: Cancer: Principles and Practice of Oncology, Philadelphia, Lippincott-Raven, pp 1-9. |
Prostate Cancer |
1999 |
|
60. Labrie, F. (1999) Prostate cancer: Endocrinology of prostate cancer-intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Textbook of Clinical Endocrinology, Milan, Italy, McGraw-Hill Libri Italia Srl, pp 13-16. |
Prostate Cancer |
1999 |
|
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. |
Prostate Cancer |
1999 |
|
62. Labrie, F., Candas, B. (1999) Bicalutamide versus Flutamide in combination therapy [Letter to the Editor re: Schellhammer et al. 50: 330-336, 1997]. Urology, 53: 662-663. |
Prostate Cancer |
1999 |
|
63. Labrie, F., Candas, B. (1999) The Quebec study shows a 69% decrease in prostate cancer death [Authors' Response to comment of Alexander and Prescott on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 137. |
Prostate Cancer |
1999 |
|
64. Labrie, F., Candas, B. (1999) Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial [Authors' Response to comment of Boer and Schroder on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 132-134. |
Prostate Cancer |
1999 |
|
65. Labrie, F., Candas, B., Dupont, A., Cusan, L., Gomez, J.L., Suburu, R.E., Diamond, P., Lévesque, J., Bélanger, A. (1999) Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 38: 83-91. |
Prostate Cancer |
1999 |
|
66. Labrie, F., Cusan, J., Gomez, J., Levesque, J., Candas, B. (1999) Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Society of the Study of the Aging Male, 2: 33-43. |
Prostate Cancer |
1999 |
|
67. Labrie, F., Cusan, L., Gomez, J.-L., Bélanger, A., Candas, B. (1999) Long-term combined androgen blockade alone for localized prostate cancer. Mol. Urol., 3: 217-226. |
Prostate Cancer |
1999 |
|
68. Labrie, F., Simard, J., Coquet, A., Leblanc, G., Candas, B. (1999) Relative potency of bicalutamide (Casodex) and Flutamide (Eulexin) [Letter to the Editor: Reply by the authors re: 50: 913-919, 1997]. Urology, 54: 195-197. |
Prostate Cancer |
1999 |
|
4726. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. |
Prostate Cancer |
1999 |
|
70. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum. Pathol., 30: 1503-1507. |
Prostate Cancer |
1999 |
|
71. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Prostatic intraepithelial neoplasia and endocrine manipulation. Eur. Urol., 35: 508-510. |
Prostate Cancer |
1999 |
|
72. van der Kwast, T.H., Têtu, B., Candas, B., Gomez, J.-L., Cusan, L., Labrie, F. (1999) Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology, 53: 523-529. |
Prostate Cancer |
1999 |
|
73. Chen, C., Li, X., Singh, S.M., Labrie, F. (1998) Activity of 17beta-(N-alkyl/arylformamido)- and 17beta-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors in the hamster flank organ and ear. J. Invest. Dermatol., 111: 273-278. |
Prostate Cancer |
1998 |
|
74. Eeles, R.A., Durocher, F., Edwards, S., Teare, D., Badzioch, M., Hamoudi, R., Gill, S., Biggs, P., Dearnaley, D., Ardern-Jones, A., Dowe, A., Shearer, R., McLennan, D.L., Norman, R.L., Ghadirian, P., Aprikian, A., Ford, D., Amos, C., King, T.M., The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators, Labrie, F., Simard, J., Narod, S.A., Easton, D., Foulkes, W.D. (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am. J. Hum. Genet, 62: 653-658. |
Prostate Cancer |
1998 |
|
75. Labrie, F. (1998) Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocrine-Related Cancer, 5: 341-351. |
Prostate Cancer |
1998 |
|
76. Labrie, F. (1998) Optimizing combined androgen blockade in prostate cancer, in: Belldegrun, A., Kirby, R.S. et Oliver, R.T.D., eds: New Perspectives in Prostate Cancer, England, ISIS Medical Media, pp 293-311. |
Prostate Cancer |
1998 |
|
77. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. |
Prostate Cancer |
1998 |
|
78. Pelletier, G., Luu-The, V., Huang, X.F., Lapointe, H., Labrie, F. (1998) Localization by in situ hybridization of steroid 5alpha-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol., 160: 577-582. |
Prostate Cancer |
1998 |
|
79. Têtu, B., Van der kwast, T., Fradet, Y., Candas, B., Gomez, J.L., Cusan, L., Labrie, F. (1998) Morphologic effects of neoadjuvant hormone therapy on prostate cancer. Mol. Urol., 2: 103-107. |
Prostate Cancer |
1998 |
|
80. van der Kwast, T., Têtu, B., Suburu, E.R., Gomez, J., Lemay, M., Labrie, F. (1998) Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J. Pathol., 186: 406-409. |
Prostate Cancer |
1998 |
|
81. Labrie, F. (1997) Flutamide plus castration in patients with previously untreated prostate cancer [Letter to the Editor re: Noldus et al. 47: 713-8, 1996]. Urology, 50: 479. |
Prostate Cancer |
1997 |
|
82. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Lemay, M. (1997) Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen [Letter to the Editor: Reply to Brown and Feuer re 47: 212-7, 1996]. Urology, 49: 306-307. |
Prostate Cancer |
1997 |
|
83. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1997) Long-term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer. Mol. Urol., 1: 253-261. |
Prostate Cancer |
1997 |
|
84. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Bélanger, A., Candas, B. (1997) Neoadjuvant hormonal therapy: the Canadian experience. Urology, 49: 56-64. |
Prostate Cancer |
1997 |